This work provides new evidence regarding the impact of IGFs declination in aging, clearly suggesting a strong clinical relevance since IGF-II therapy reduces age-related side effects in rats without increasing testosterone levels, potentetially worsening diseases such as prostate hypertrophy or neoplasia. Here, IGF2 is linked to benign prostatic hyperplasia.